Lukasz Kuryk, PhD, MBA, Chief Development Officer (CDO) at Valo Therapeutics Finland, holds a PhD in Biopharmaceutics/Oncolytic Virotherapy from the University of Helsinki, Finland. He also earned an MBA from the Institute of Computer Science, Polish Academy of Sciences (PAN), Poland, in collaboration with the Woodbury School of Business, University of Utah, USA.
In addition, he has completed multiple advanced training programs, including courses at Harvard Medical School focused on clinical studies and biomarker discoveries, as well as postgraduate studies in clinical trial design, execution, and management at Wroclaw Medical University.
Dr. Kuryk brings extensive experience in immuno-oncology and immuno-virotherapy, with a strong background in preclinical, translational, and early-stage clinical drug development (Phases I–II) in oncology. Prior to joining Valo Therapeutics, he spent over a decade in clinical-stage immuno-oncology companies, including Targovax, Circio as Director of Clinical Science, Senior Research Scientist, and Oncos Therapeutics as a Research Scientist. His work focused on both preclinical research and clinical studies utilizing oncolytic vectors and peptide-based cancer vaccines.
Dr. Kuryk held research positions at the Institute of Biomedical Research “Alberto Sols” (Spain) and the Military Institute of Hygiene and Epidemiology (Poland). He has also been a visiting researcher at several prestigious institutions, including the WHO Regional Office for Europe at the Robert Koch Institute (Germany), the Bellvitge Biomedical Research Institute (IDIBELL, Spain), and the University of Padova (Italy), where he conducted multiple research projects in immuno-oncology and virology.
Dr. Kuryk currently serves as an Associate Professor at the National Institute of Public Health in Poland, where he leads and contributes to several research initiatives in immunotherapy.
At Valo Therapeutics Finland he is responsible for the management of clinical operations, translational and clinical development strategies, and intellectual property portfolio management.
